Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 8 | 2022 | 62 | 1.530 |
Why?
|
| Animals | 18 | 2022 | 1711 | 0.610 |
Why?
|
| Mice | 12 | 2022 | 685 | 0.550 |
Why?
|
| Brain | 8 | 2021 | 195 | 0.520 |
Why?
|
| tau Proteins | 2 | 2022 | 6 | 0.490 |
Why?
|
| Memory Disorders | 2 | 2013 | 36 | 0.480 |
Why?
|
| Fixatives | 1 | 2015 | 1 | 0.480 |
Why?
|
| Histocytochemistry | 1 | 2015 | 1 | 0.480 |
Why?
|
| Imidazolidines | 1 | 2015 | 1 | 0.480 |
Why?
|
| Formaldehyde | 1 | 2015 | 2 | 0.480 |
Why?
|
| Tromethamine | 1 | 2015 | 2 | 0.480 |
Why?
|
| Ascorbic Acid | 1 | 2015 | 8 | 0.470 |
Why?
|
| Tauopathies | 1 | 2014 | 2 | 0.440 |
Why?
|
| Memory | 2 | 2018 | 39 | 0.430 |
Why?
|
| Behavior, Animal | 2 | 2013 | 20 | 0.430 |
Why?
|
| Prostaglandins I | 1 | 2013 | 1 | 0.410 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2013 | 1 | 0.400 |
Why?
|
| Xanthines | 1 | 2013 | 3 | 0.400 |
Why?
|
| Memory, Long-Term | 1 | 2013 | 4 | 0.400 |
Why?
|
| Physical Conditioning, Animal | 4 | 2020 | 29 | 0.390 |
Why?
|
| Anxiety | 2 | 2013 | 167 | 0.370 |
Why?
|
| Mice, Transgenic | 4 | 2022 | 47 | 0.360 |
Why?
|
| alpha-Synuclein | 2 | 2021 | 3 | 0.350 |
Why?
|
| Disease Models, Animal | 7 | 2022 | 225 | 0.330 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 3 | 0.320 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2009 | 2 | 0.310 |
Why?
|
| Microglia | 1 | 2009 | 11 | 0.310 |
Why?
|
| Spinal Cord Injuries | 1 | 2009 | 18 | 0.310 |
Why?
|
| Neurons | 1 | 2009 | 109 | 0.280 |
Why?
|
| Plaque, Amyloid | 2 | 2018 | 7 | 0.260 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 184 | 0.230 |
Why?
|
| Spinal Cord | 2 | 2014 | 9 | 0.190 |
Why?
|
| Indans | 1 | 2021 | 7 | 0.180 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 13 | 0.180 |
Why?
|
| Methylazoxymethanol Acetate | 1 | 2021 | 1 | 0.170 |
Why?
|
| Cycas | 1 | 2021 | 1 | 0.170 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2021 | 2 | 0.170 |
Why?
|
| Cyclooxygenase 2 | 1 | 2021 | 7 | 0.170 |
Why?
|
| Ubiquitin | 1 | 2021 | 6 | 0.170 |
Why?
|
| Lactones | 1 | 2021 | 10 | 0.170 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2021 | 6 | 0.170 |
Why?
|
| Optical Imaging | 1 | 2021 | 17 | 0.170 |
Why?
|
| Sulfones | 1 | 2021 | 10 | 0.170 |
Why?
|
| Biocompatible Materials | 1 | 2021 | 21 | 0.170 |
Why?
|
| Fluorescent Dyes | 1 | 2021 | 32 | 0.170 |
Why?
|
| Amyloid beta-Peptides | 2 | 2018 | 15 | 0.160 |
Why?
|
| Receptors, Purinergic P2Y2 | 1 | 2020 | 2 | 0.160 |
Why?
|
| Cerebrovascular Circulation | 1 | 2020 | 6 | 0.160 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 12 | 0.160 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 29 | 0.150 |
Why?
|
| Neoplasms | 1 | 2021 | 90 | 0.150 |
Why?
|
| Microscopy | 1 | 2019 | 35 | 0.150 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 68 | 0.150 |
Why?
|
| Neuroendocrine Secretory Protein 7B2 | 1 | 2018 | 1 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 197 | 0.140 |
Why?
|
| Humans | 7 | 2021 | 4936 | 0.130 |
Why?
|
| CA1 Region, Hippocampal | 2 | 2013 | 8 | 0.130 |
Why?
|
| Maze Learning | 2 | 2013 | 22 | 0.130 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 1 | 0.120 |
Why?
|
| Angiotensins | 1 | 2015 | 4 | 0.120 |
Why?
|
| Tissue Fixation | 1 | 2015 | 4 | 0.120 |
Why?
|
| Antigens | 1 | 2015 | 4 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 36 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 32 | 0.120 |
Why?
|
| Autophagy | 1 | 2016 | 30 | 0.120 |
Why?
|
| Liposomes | 1 | 2016 | 24 | 0.120 |
Why?
|
| Hot Temperature | 1 | 2015 | 46 | 0.110 |
Why?
|
| Polymyxin B | 1 | 2015 | 28 | 0.110 |
Why?
|
| Nerve Degeneration | 1 | 2014 | 8 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2016 | 69 | 0.110 |
Why?
|
| Cyclooxygenase 1 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 9 | 0.100 |
Why?
|
| Fear | 1 | 2013 | 7 | 0.100 |
Why?
|
| Interneurons | 1 | 2013 | 6 | 0.100 |
Why?
|
| Entorhinal Cortex | 1 | 2013 | 3 | 0.100 |
Why?
|
| Motor Activity | 1 | 2013 | 61 | 0.100 |
Why?
|
| Neural Pathways | 1 | 2013 | 31 | 0.100 |
Why?
|
| Ethanolamines | 1 | 2012 | 1 | 0.100 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2012 | 2 | 0.100 |
Why?
|
| Asthma | 1 | 2012 | 8 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2013 | 177 | 0.090 |
Why?
|
| Hippocampus | 1 | 2013 | 59 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2021 | 84 | 0.080 |
Why?
|
| Macrophages | 1 | 2009 | 26 | 0.080 |
Why?
|
| Mutation | 1 | 2009 | 132 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2018 | 140 | 0.060 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2013 | 5 | 0.050 |
Why?
|
| Calcineurin | 2 | 2013 | 11 | 0.050 |
Why?
|
| Rats, Wistar | 2 | 2013 | 31 | 0.050 |
Why?
|
| Female | 3 | 2018 | 2523 | 0.050 |
Why?
|
| Vimentin | 1 | 2022 | 5 | 0.050 |
Why?
|
| Rats | 2 | 2013 | 241 | 0.050 |
Why?
|
| Biomarkers | 1 | 2022 | 81 | 0.050 |
Why?
|
| Protein Aggregates | 1 | 2021 | 3 | 0.050 |
Why?
|
| Protein Folding | 1 | 2021 | 14 | 0.040 |
Why?
|
| Drug Design | 1 | 2021 | 16 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 44 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 52 | 0.040 |
Why?
|
| Ligands | 1 | 2021 | 55 | 0.040 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2021 | 1 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2021 | 4 | 0.040 |
Why?
|
| Mutagens | 1 | 2021 | 3 | 0.040 |
Why?
|
| Materials Testing | 1 | 2021 | 17 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2021 | 4 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2021 | 18 | 0.040 |
Why?
|
| Particle Size | 1 | 2021 | 41 | 0.040 |
Why?
|
| Posterior Cerebral Artery | 1 | 2020 | 2 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2020 | 6 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 14 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 17 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2020 | 47 | 0.040 |
Why?
|
| Microscopy, Ultraviolet | 1 | 2019 | 2 | 0.040 |
Why?
|
| Microtomy | 1 | 2019 | 2 | 0.040 |
Why?
|
| Microcirculation | 1 | 2019 | 7 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 17 | 0.040 |
Why?
|
| Lung | 1 | 2019 | 35 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 49 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 42 | 0.040 |
Why?
|
| Liver | 1 | 2019 | 49 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2021 | 216 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2019 | 57 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 97 | 0.040 |
Why?
|
| Benzothiazoles | 1 | 2018 | 1 | 0.040 |
Why?
|
| Clusterin | 1 | 2018 | 2 | 0.040 |
Why?
|
| Transgenes | 1 | 2018 | 6 | 0.040 |
Why?
|
| Solubility | 1 | 2018 | 10 | 0.040 |
Why?
|
| Heterozygote | 1 | 2018 | 8 | 0.040 |
Why?
|
| Genotype | 1 | 2018 | 40 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 6 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 26 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2016 | 18 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 125 | 0.030 |
Why?
|
| Kidney | 1 | 2015 | 51 | 0.030 |
Why?
|
| Male | 2 | 2013 | 2491 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 161 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2013 | 13 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 17 | 0.030 |
Why?
|
| Long-Term Potentiation | 1 | 2013 | 5 | 0.030 |
Why?
|
| Voltage-Sensitive Dye Imaging | 1 | 2013 | 3 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2013 | 18 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 176 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2013 | 21 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 28 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 12 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 19 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 26 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 70 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 65 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2013 | 21 | 0.020 |
Why?
|
| Exercise Test | 1 | 2013 | 41 | 0.020 |
Why?
|
| Formoterol Fumarate | 1 | 2012 | 1 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mucins | 1 | 2012 | 4 | 0.020 |
Why?
|
| Bronchi | 1 | 2012 | 2 | 0.020 |
Why?
|
| Epinephrine | 1 | 2012 | 8 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2013 | 43 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2012 | 44 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 67 | 0.020 |
Why?
|